Deksmedetomidin Böbrek Hücreleri (Hek-293) Üzerinde Toksik midir ? Sitotoksisite, Reaktif Oksijen Türleri (ROS) ve Apoptoz Üzerine Etkileri

Abstract

Aim: Dexmedetomidine; it is widely used in anesthesia and intensive care. We aimed to examine and compare the cytotoxic, reactive oxygen species (ROS) and apoptotic effects of dexmedetomidine on kidney cells (Hek-293) in vitro at two different high and cumulative doses. Material and Methods: The half-maximum inhibitory concentration (IC50) dose of dexmedetomidine on Hek-293 cells was determined using the 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide (MTT) method. Then at two different doses of the drug; apoptotic effects were determined by Annexin-V Method, morphological examinations were determined by Acridine Orange Ethidium Bromide Method and intracellular ROS levels were determined by flow cytometry. Results: The IC50 value of dexmedetomidine for Hek-293 cells was determined as 64.6559 μg/mL. Compared with the control group, doses of 50 and 100 µg/mL of dexmedetomidine tended to show cytotoxicity (p<0.05). dexmedetomidine was found to have a lower cytotoxic effect at a dose of 50 μg / mL than at a dose of 100 μg / mL (p<0.05). Conclusion: In the study, it was determined that dexmedetomidine increased intracellular ROS more than clinical doses at two different concentrations on Hek-293 cells, cytotoxic doses caused an increase in ROS in cells and induced apoptosis. We think that the toxic effects of dexmedetomidine can be prevented with the data obtained from this study and further studies.